Investors Investors

Stock Quote

Stock Quote

8:41 PM EST on Nov 20

Press Releases

Press Releases

All Releases
Nov 19, 2018
NEW YORK, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that safety and tolerability data from a pooled analysis of four
Nov 08, 2018
AZEDRA ® (iobenguane I 131) Approved by U.S. Food and Drug Administration (FDA) AZEDRA U.S. Launch Progressing and AZEDRA Added to the NCCN Guidelines and Four CMS-Recognized Drug Compendia Phase 3 Study of PyL TM for the Detection of Biochemical Recurrence of Prostate Cancer to Begin by Year End
Nov 06, 2018
NEW YORK, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that management will present at the following upcoming investor
Nov 01, 2018
NEW YORK , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, announced today that it will host a conference call and webcast to review the third
Oct 11, 2018
– Trial will utilize PyL imaging in order to target the patients most likely to benefit, advancing the Company’s theranostic approach to the treatment of prostate cancer – NEW YORK, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing
Oct 09, 2018
NEW YORK, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that the Company’s pivotal trial of AZEDRA ®  (iobenguane I 131), the
Oct 05, 2018
-PyL highly sensitive, 93-99%, in reliably detecting  metastatic prostate cancer lesions and highly specific, 96-99%, in confirming the absence of pelvic lymph node disease - -Study data highlights the strong positive predictive values of PyL to detect prostate cancer in pelvic lymph nodes and
Sep 25, 2018
NEW YORK, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that Mark R. Baker, Chief Executive Officer, will present at the Cantor
Sep 17, 2018

NEW YORK, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that AZEDRA ® (iobenguane I 131), the Company’s radiotherapeutic, has

Sep 12, 2018

-Meets Co-Primary Endpoint of Specificity; 1404 Successfully Identifies Patients Without Clinically Significant Prostate Cancer- -Co-Primary Endpoint of Sensitivity to Identify Patients with Clinically Significant Disease Not Met- NEW YORK, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Progenics

Aug 08, 2018

NEW YORK, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced today the pricing of an underwritten public offering of 9,090,909 primary shares of its common stock at a public offering price of $8.25 per share. The gross proceeds from the sale of the primary

Aug 07, 2018

NEW YORK, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced today that it is offering to sell shares of its common stock in an underwritten public offering pursuant to an effective shelf registration statement.

Jul 31, 2018

AZEDRA ® (iobenguane I 131) Approved by U.S. Food and Drug Administration (FDA); U.S. Promotion Commences Top-Line Data from Phase 3 Trial for PSMA-Targeted SPECT/CT Imaging Agent 1404 Expected in Q3’18 Top-Line Data from Phase 2/3 Trial for PSMA-Targeted PET/CT Imaging Agent PyL ™ Expected in

Jul 30, 2018
The First FDA-Approved Treatment for These Rare, Life-Threatening Neuroendocrine Cancers in Patients Aged 12 and Older Company to Host Conference Call Tomorrow at 8:00 AM ET NEW YORK , July 30, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced that the U.S.
Jun 26, 2018
Top-line Data Expected in 4Q2018 NEW YORK , June 26, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging technology for targeting and treating cancer, today announced that it has completed enrollment in its Phase
Jun 25, 2018
Algorithm Validated Using Data from Company's 1404 Phase 2 Study NEW YORK , June 25, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging technology for targeting and treating cancer, reported data demonstrating the
Jun 04, 2018
NEW YORK , June 04, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, announced updated overall survival data from the Company’s pivotal Phase 2 trial of its targeted,
May 31, 2018
NEW YORK , May 31, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging technology for targeting and treating cancer, announced today that Mark R. Baker , Chief Executive Officer, will present at the Jefferies 2018
May 31, 2018
NEW YORK , May 31, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging technology for targeting and treating cancer, announced today that an abstract describing the Company’s imaging analysis technology will be
May 22, 2018
Data Support Prognostic Utility of aBSI as an Imaging Biomarker for Survival in Patients with Castration-Resistant Prostate Cancer NEW YORK , May 22, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) announced today that results from a trial evaluating the use of its automated